載入中
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
收盤時
US$2.29
US$0.00 · 0.00%
盤後
US$2.29
US$0.00 · 0.00%
10月12日 下午4:10 ET
盤中時間採用ET。市場資料可能有所延遲。
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
日內區間
目前US$2.29
52週區間
目前US$2.29
盤中時間採用ET。市場資料可能有所延遲。
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
日內區間
目前US$2.29
52週區間
目前US$2.29
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 401萬 USD | 1839.4萬 USD |
| 銷貨成本 | 168.6萬 USD | — | — | 65.1萬 USD | 582萬 USD |
| 毛利 | −168.6萬 USD | — | — | 335.9萬 USD | 1257.4萬 USD |
| 研究與開發 | 4739萬 USD | 3775.7萬 USD | 3284.8萬 USD | 3154.4萬 USD | 2826.8萬 USD |
| 銷售、一般及管理費用 | 829.5萬 USD | 471.4萬 USD | 466.2萬 USD | 630.5萬 USD | 938.8萬 USD |
| 營業費用 | 5399.9萬 USD | 4247.1萬 USD | 3751萬 USD | 3784.9萬 USD | 3765.6萬 USD |
| 利息收入 | 567.9萬 USD | 981.2萬 USD | 1042.1萬 USD | 382.3萬 USD | 46.7萬 USD |
| 利息支出 | 8.8萬 USD | 80.7萬 USD | — | — | — |
| 折舊和攤銷 | 168.6萬 USD | 174.5萬 USD | 174.4萬 USD | 261.4萬 USD | 264.8萬 USD |
| 營業利益 | −5568.5萬 USD | −4247.1萬 USD | −3751萬 USD | −3449萬 USD | −2508.2萬 USD |
| 淨利 | −4554萬 USD | −3853.1萬 USD | −2455.7萬 USD | −3290萬 USD | −1741.4萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅3項
報告持有此股票曝險的交易所交易基金。
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
EA Bridgeway Omni Small-Cap Value ETFBSVO
Avantis U.S. Small Cap Equity ETFAVSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
